Goldman Sachs’s China Pharma Holdings CPHI Stock Holding History

Goldman Sachs’s Portfolio CPHI Stock Details CPHI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-20	Closed	-$2K	–	6677
2017 Q2	$2K	Hold	20	–	–	﹤0.01%	6728
2017 Q1	$3K	Hold	20	–	–	﹤0.01%	6681
2016 Q4	$3K	Hold	20	–	–	﹤0.01%	6832
2016 Q3	$2K	Sell	20 -1	-5%	-$128	﹤0.01%	6961
2016 Q2	$3K	Sell	21 -72	-77%	-$8.08K	﹤0.01%	6959
2016 Q1	$8K	Buy	+93	New	+$6.99K	﹤0.01%	6925

Other funds holding CPHI

PAM

Pope Asset Management Memphis, Tennessee $162M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Glenhill Advisors New York $6.94M AUM 24.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Goldman Sachs's CPHI Position: Q3 2017 in Review

Goldman Sachs sold out of China Pharma Holdings (CPHI) in Q3 2017, closing a stake of 20 shares — an estimated $2K sold.

Goldman Sachs first reported a position in CPHI in Q1 2016 and held it in 6 quarters. The position peaked at $8K in Q1 2016. 6 funds tracked by Wall St. Rank hold CPHI as of Q3 2017.

Goldman Sachs reported no remaining China Pharma Holdings position as of Q3 2017 after selling out during the quarter.
Goldman Sachs sold 20 China Pharma Holdings shares in Q3 2017, an estimated $2K.
Goldman Sachs first reported a position in China Pharma Holdings in Q1 2016 and held it in 6 quarters.
Goldman Sachs's China Pharma Holdings position peaked at $8K in Q1 2016.
6 funds tracked by Wall St. Rank held China Pharma Holdings as of Q3 2017.

Based on Goldman Sachs's 13F filing for Q3 2017, filed 14 Nov 2017.